Expert Ideas

Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth
Kratos Analyst Sees Growth Potential As Tactical Drones, Hypersonics Gain Traction
Darden Restaurants Olive Garden Growth Drive Optimism Amid Valuation Concerns: Analyst
Kratos Analyst Sees Growth Potential As Tactical Drones, Hypersonics Gain Traction
Darden Restaurants Olive Garden Growth Drive Optimism Amid Valuation Concerns: Analyst
KB Home Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Tom Lee Predicts Stock Market Rebound Amid Tariff, Fed Policy Shifts

Expert Ideas Recent News

Fed's Goolsbee Urges Patience As Trump's Tariffs Stir Fears Of Stagflation: 'We Need To Be Careful When You Say Transitory'
Chicago Fed President Goolsbee urges Fed to take long-term approach amid trade tensions, business uncertainty and inflation, cautioning against overreaction.
Is Freeport-McMoRan's US-Based Footprint An Advantage? Analyst Upgrades Stock Amid Copper Import Tariff Risk
JP Morgan upgraded FCX to Overweight with price target of $52 from $48, citing sustained premium pricing and supply constraints, and potential protective measures for US copper imports.
S&P 500 Could Soar 12% By Year-End—But Only If Recession Is Avoided, Goldman Sachs Says
Whenever the S&P 500 falls 10% and the economy sidesteps a recession, the index typically rebounds with a 12% gain over the following year.
Visa Vs. Mastercard: The Battle For Payment Supremacy Heats Up
Visa dominates with higher volume and revenue, but Mastercard leads in growth. Investors must choose between Visa's dominance or Mastercard's momentum.
Wall Street's Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields
Top 2 Energy Stocks That May Collapse In Q1
Buying Bitcoin Now? 'The Single Best Time In History,' Bitwise's Matt Hougan Says
Bitwise‘s Chief Investment Officer Matt Hougan sees Bitcoin (CRYPTO: BTC) well-positioned for the future, citing several political developments as fundamentally bullish factors.
US Steel Stock Surges Forming Golden Cross, Does Billionaire Investment In X Signal More Upside?
US Steel stock (X) shows bullish signals with 8.35% gain in 5 days and forming a Golden Cross. Strong momentum, earnings outlook, and merger drama drive the stock's rise. Billionaire Druckenmiller doubles stake as Trump hints at supporting blocked merger. Next move could be explosive.
Top 3 Consumer Stocks That May Rocket Higher This Quarter
Top Wall Street Forecasters Revamp Carnival Price Expectations Ahead Of Q1 Earnings
Intuitive Machines Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Bitcoin, Ethereum, XRP, Dogecoin Pull Back After FOMC: $84,000 Support Is Key, Traders Note
Cryptocurrencies slightly retraced gains on Thursday as President Trump addressed cryptocurrency investors via a pre-recorded statement.
EXCLUSIVE: 'Volatility Will Likely Be Hanging Around' — TrueShares CEO On Rising Demand For Buffered ETFs
Market volatility has led to re-evaluation of risk management. Buffered ETFs, like TrueShares Structured Outcome ETF, offer downside protection and upside potential. CEO of TrueMark Investments explains why these ETFs are in demand.
Peter Schiff Says Strategic Bitcoin Reserve Is A 'Scam' To Lure Americans Into Buying More Crypto
Bitcoin (CRYPTO: BTC) critic Peter Schff is warning that the strategic Bitcoin reserve is a tool to trick Americans into speculative losses.
Is Tariff An Issue For Restaurant Sector? J.P. Morgan Highlights Winners & Losers
J.P. Morgan analyst John Ivankoe hosted Bloomin' Brands, CAVA Group and others at the Las Vegas forum. A major takeaway: focus on "doing fewer things better" with continued investments in customer and employee experiences. The analyst recommends adding fresh investments in BROS, SBUX, and CAVA, while maintaining cautious optimism on CMG and EAT.
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside
B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.
Amentum Faces Growth Slump As Government Cuts Spending, Analyst Expects Merger To Boost Margins
Goldman Sachs analyst Noah Poponak initiated coverage on Amentum Holdings with a Neutral Rating, and a price forecast of $21.
JPMorgan: Spire Positioned For Growth With Favorable Missouri Legislation, Rate Case Developments
JPMorgan upgrades Spire Inc. to Overweight, raises price forecast to $85. Analyst cites regulatory improvements in Missouri and positive factors for increased earnings and growth potential.
Holley May Bear The Brunt Of Ongoing Macroeconomic Challenges, Analyst Highlights Softer Top-line Outlook
JP Morgan analyst maintains Neutral rating on Holley, citing macroeconomic challenges and a softer revenue outlook despite strong EBITDA guidance.
Analysts See Profit Pressure For Williams-Sonoma In 2025, But Brand Strength Remains Intact
Analysts lower price forecast for Williams-Sonoma after strong Q4 results, with revenue up 8% YoY and EPS beating expectations.
Rivian Analyst Downgrades Stock With 'Triple Whammy' Of Policy Risk: 'No Catalysts In 2025'
A Rivian analyst downgrades the stock with no positive catalysts coming in 2025 and the potential for negative risk from federal policy decisions.
GDS Holdings Analyst Upgrade Highlights Higher AI Demand Driven By DeepSeek, Other Platforms In China
Raymond James upgrades GDS Holdings to Strong Buy, citing AI demand growth and strategic moves, despite Q4 results causing confusion.
;

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved